中性粒细胞与淋巴细胞比值在晚期不可切除结直肠癌患者化疗疗效及预后的意义

doi:10.3969/j.issn.1000-8535.2020.01.014

摘要/Abstract

摘要： 目的评估中性粒细胞与淋巴细胞比值(NLR)在晚期结直肠癌(CRC)患者化疗疗效及预后的意义。方法回顾性收集2016年1月—2019年4月期间接受以奥沙利铂为基础的标准一线化疗的晚期不可切除结直肠癌患者50例临床病历资料,并在2个化疗周期后评估化疗疗效;根据入组患者化疗前血液学数据计算中性粒细胞与淋巴细胞比值(NLR),运用受试者工作特征曲线确定的NLR最佳截断值,将患者分为高NLR(≥3.785) 组和低NLR(＜3.785) 组,比较高、低NLR与临床病理特征、化疗疗效及无进展生存期(PFS)、总生存期(OS)差异;采用COX回归分析模型分析影响晚期结直肠癌患者PFS、OS的因素。结果高、低NLR两组肿瘤分化程度(P=0.030)、ECOG评分(P=0.003)、CEA(P=0.011)、CA19-9(P=0.047)比较,差异有统计学意义;高低NLR两组间化疗疗效比较,差异有统计学意义(P＜0.001),高NLR组化疗疗效较差;两组中位PFS分别为3.44个月和12.84个月,差异有统计学意义(χ²=39.730,P＜0.001),两组中位OS分别为7.59个月和22.32个月,差异有统计学意义(χ²=40.505,P＜0.001);Cox回归分析提示NLR高低、CEA水平是PFS、OS的独立预后因素(P＜0.05)。结论高水平NLR与晚期结直肠癌患者化疗疗效不佳和预后不良相关,可作为其化疗疗效及预后监测的指标。

关键词: 结直肠癌, 中性粒细胞与淋巴细胞比值, 化疗疗效, 预后

Abstract: Objective To evaluate the value of neutrophil-lymphocyte ratio (NLR) in the chemotherapy curative effect and prognosis of patients with advanced colorectal cancer (CRC). Methods Retrospective collection of clinical data from 50 patients with advanced unresectable colorectal cancer who received oxaliplatin-based standard first-line chemotherapy between January 2016 and April 2019. Chemotherapy curative effect was evaluated following 2 chemotherapy cycles. Calculation of neutrophil to lymphocyte ratio (NLR) based on pre-chemotherapy hematology data. The receiver operating characteristic curve was used to determine the optimal cutoff value of NLR,according to patients who were divided into groups of high NLR(NLR≥3.785)and low NLR(NLR≥3.785).The differences between high and low NLR and clinicopathological features, efficacy of chemotherapy, progression-free survival (PFS), and total survival (OS) were compared. COX regression analysis mode was used to analysis of factors affecting PFS and OS in patients with advanced colorectal cancer. Results The differences in tumor differentiation (P=0.030), ECOG score (P=0.003), CEA (P=0.011), CA19-9 (P=0.047) in the high and low NLR groups were statistically significant. The differences in chemotherapy between the two groups was statistically significant (P<0.001), and the high NLR group was less effective. The median PFS of the high and low NLR groups were 3.44 months and 12.84 months, respectively, and the difference was statistically significant (χ²=39.730, P<0.001). The median OS of the high and low NLR groups was 7.59 months and 22.32 months, respectively, and the difference was statistically significant (χ²=40.505, P<0.001). Cox regression analysis suggested that NLR levels and CEA levels were independent prognostic factors for PFS and OS(P＜0.05). Conclusion High-level NLR is associated with poor chemotherapy response and poor prognosis in patients with advanced colorectal cancer, and was used as an indicator of chemotherapy efficacy and prognosis.

Key words: Colorectal cancer, Neutrophil-lymphocyte ratio, Chemotherapy curative effect, Prognosis

李赟, 李勇, 巩平, 李小英, 李娜. 中性粒细胞与淋巴细胞比值在晚期不可切除结直肠癌患者化疗疗效及预后的意义[J]. 广州医药, 2020, 51(1): 59-65.

LI Yun, LI Yong, GONG Ping, LI Xiaoying, LI Na. Significance of neutrophil-lymphocyte ratio in chemotherapy curative effect and prognosis in patients with advanced unresectable colorectal cancer[J]. Guangzhou Medical Journal, 2020, 51(1): 59-65.

参考文献

[1] LOMBARDI L, MORELLI F, CINIERI S, et al. Adjuvant colon cancer chemotherapy: where we are and where we'll go[J]. Cancer Treat Rev,2010(36) Suppl 3:S34-S41.
[2] JOHN B J, ABULAFI A M, POULLIS A, et al. Chronic subclinical bowel inflammation may explain increased risk of colorectal cancer in obese people[J]. Gut,2007,56(7):1034-1035.
[3] BRENNAN C A, GARRETT W S. Gut Microbiota, Inflammation, and colorectal cancer[J]. Annu Rev Microbiol,2016,70:395-411.
[4] FOX J G, WANG T C. Inflammation, atrophy, and gastric cancer[J]. J Clin Invest,2007,117(1):60-69.
[5] 高肇妤,梁迪,靳晶,等. 中性粒细胞在肺癌发展及预后中的作用[J]. 肿瘤,2017,37(8):889-894..
[6] SEMENIUK-WOJTAS A, LUBAS A, STEC R, et al. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and c-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis[J]. Clin Genitourin Cancer,2018,16(3):e685-e693.
[7] YANG J, GUO X, WANG M, et al. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS[J]. Sci Rep,2017,7(1):17166.
[8] YANG J, XU H, GUO X, et al. Pretreatment inflammatory indexes as prognostic predictors for survival in colorectal cancer patients receiving neoadjuvant chemoradiotherapy[J]. Sci Rep,2018,8(1):3044.
[9] WEN J, BEDFORD M, BEGUM R, et al. The value of inflammation based prognostic scores in patients undergoing surgical resection for oesophageal and gastric carcinoma[J]. J Surg Oncol,2018,117(8):1697-1707.
[10] DING P R, AN X, ZHANG R X, et al. Elevated preo-perative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer[J]. Int J Colorectal Dis,2010,25(12):1427-1433.
[11] SHIMADA H, TAKIGUCHI N, KAINUMA O, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer[J]. Gastric Cancer,2010,13(3):170-176.
[12] MANTOVANI A, ALLAVENA P, SICA A, et al. Cancer-related inflammation[J]. Nature,2008,454(7203):436-444.
[13] WEST N R, SARAH M C, FANNY F, et al. Emerging cytokine networks in colorectal cancer[J]. Nature Rev Immunol,2015,15(10):615-629.
[14] SHABNAM S, MICHAEL K. Immunity, inflammation, and cancer: an eternal fight between good and evil[J]. J Clin Invest,2015,125(9):3347.
[15] BALKWILL F R. The chemokine system and cancer[J]. J Pathol,2011,226(2):148-157.
[16] PINE J K, MORRIS E, HUTCHINS G G, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour[J]. Br J Cancer,2015,113(2):204-211.
[17] YING H Q, DENG Q W, HE B S, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients[J]. Med Oncol,2014,31(12):305.
[18] SHIBUTANI M, MAEDA K, NAGAHARA H, et al. Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer[J]. Oncol Lett,2017,13(2):1000-1006.
[19] LEE Y, SUN H K, HAN J Y, et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy[J]. J Cancer Res Clin Oncol,2012,138(12):2009-2016.
[20] YASEMIN K, IDRIS Y, KUBILAY E, et al. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis[J]. Asian Pac J Cancer Prev,2014,15(6):2651-2654.
[21] LARCO J E D, WUERTZ B R K, FURCHT L T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8[J]. Clin Cancer Res,2004,10(15):4895.
[22] RINA O, KAZUHISA T, KAYO M, et al. Prognostic factors in patients with inoperable non-small cell lung cancer-an analysis of long-term survival patients[J]. Cancer Chemother,2006,33(11):1595.
[23] PEKER K D, OZKANLI S S, AKYUZ C, et al. Preoperative immunonutrition regulates tumor infiltrative lymphocytes and increases tumor angiogenesis in gastric cancer patients[J]. Arch Med Sci Ams,2017,13(6):1365-1372.
[24] KOBAYASHI N, USUI S, KIKUCHI S, et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer[J]. Lung Cancer,2012,75(2):223-227.
[25] DEMIRCI N S, ERDEM G U. Prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in patients with operable ampullary carcinoma[J]. Bosn J Basic Med Sci,2017,18(3):268-274.
[26] WANG L, LIANG D, XU X, et al. The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer[J]. Oncol Lett,2017,14(6):6449-6456.
[27] KISHI Y, KOPETZ S, YUN S C, et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy[J]. Ann Surg Oncol,2009,16(3):614-622.
[28] CHUA W, CHARLES K A, BARACOS V E, et al. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer[J]. Br J Cancer,2011,104(8):1288-1295.
[29] HANNA K, GOLDBERG R M. Systemic therapy for metastatic colorectal cancer: current options, current evidence[J]. J Clin Oncol,2005,23(20):4553.
[30] MITRY E, DOUILLARD J Y, van CUTSEM E, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials[J]. Ann Oncol,2004,15(7):1013-1017.
[31] KANEKO M, NOZAWA H, SASAKI K, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy[J]. Oncol,2012,82(5):261-268.
[32] 王伟. 结直肠癌患者术前中性粒细胞与淋巴细胞比(NLR)淋巴细胞与单核细胞比(LMR)与临床病理特征及预后的关系[D]. 安徽医科大学,2018.
[33] 欧锐. 结肠癌术前中性粒细胞淋巴细胞比、血小板淋巴细胞比与淋巴结转移相关临床研究[D]. 广西医科大学,2017.